ICER says it's fair for Bio­Marin and CSL to price in­com­ing he­mo­phil­ia gene ther­a­pies at $2M-$3M

Get ready for mil­lion-plus-dol­lar gene ther­a­pies to be­come the norm rather than the ex­cep­tion, and in some cas­es, the Boston-based drug pric­ing watch­dog ICER is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.